PURPOSE: Ligand-mediated activation of the androgen receptor (AR) is critical for prostate cancer (PCa) survival and proliferation. The failure to completely ablate tissue androgens may limit suppression of PCa growth. We evaluated combinations of CYP17A and 5-α-reductase inhibitors for reducing prostate androgen levels, AR signaling, and PCa volumes. PATIENTS AND METHODS: Thirty-five men with intermediate/high-risk clinically localized PCa were randomly assigned to goserelin combined with dutasteride (ZD), bicalutamide and dutasteride (ZBD), or bicalutamide, dutasteride, and ketoconazole (ZBDK) for 3 months before prostatectomy. Controls included patients receiving combined androgen blockade with luteinizing hormone-releasing hormone agonist and bicalutamide. The primary outcome measure was tissue dihydrotestosterone (DHT) concentration. RESULTS:Prostate DHT levels were substantially lower in all experimental arms (0.02 to 0.04 ng/g v 0.92 ng/g in controls; P < .001). The ZBDK group demonstrated the greatest percentage decline in serum testosterone, androsterone, and dehydroepiandrosterone sulfate (P < .05 for all). Staining for AR and the androgen-regulated genes prostate-specific antigen and TMPRSS2 was strongly suppressed in benign glands and moderately in malignant glands (P < .05 for all). Two patients had pathologic complete response, and nine had ≤ 0.2 cm(3) of residual tumor (defined as a near-complete response), with the largest numbers of complete and near-complete responses in the ZBDK group. CONCLUSION: Addition of androgen synthesis inhibitors lowers prostate androgens below that achieved with standard therapy, but significant AR signaling remains. Tissue-based analysis of steroids and AR signaling is critical to informing the search for optimal local and systemic control of high-risk prostate cancer.
RCT Entities:
PURPOSE: Ligand-mediated activation of the androgen receptor (AR) is critical for prostate cancer (PCa) survival and proliferation. The failure to completely ablate tissue androgens may limit suppression of PCa growth. We evaluated combinations of CYP17A and 5-α-reductase inhibitors for reducing prostate androgen levels, AR signaling, and PCa volumes. PATIENTS AND METHODS: Thirty-five men with intermediate/high-risk clinically localized PCa were randomly assigned to goserelin combined with dutasteride (ZD), bicalutamide and dutasteride (ZBD), or bicalutamide, dutasteride, and ketoconazole (ZBDK) for 3 months before prostatectomy. Controls included patients receiving combined androgen blockade with luteinizing hormone-releasing hormone agonist and bicalutamide. The primary outcome measure was tissue dihydrotestosterone (DHT) concentration. RESULTS: Prostate DHT levels were substantially lower in all experimental arms (0.02 to 0.04 ng/g v 0.92 ng/g in controls; P < .001). The ZBDK group demonstrated the greatest percentage decline in serum testosterone, androsterone, and dehydroepiandrosterone sulfate (P < .05 for all). Staining for AR and the androgen-regulated genes prostate-specific antigen and TMPRSS2 was strongly suppressed in benign glands and moderately in malignant glands (P < .05 for all). Two patients had pathologic complete response, and nine had ≤ 0.2 cm(3) of residual tumor (defined as a near-complete response), with the largest numbers of complete and near-complete responses in the ZBDK group. CONCLUSION: Addition of androgen synthesis inhibitors lowers prostate androgens below that achieved with standard therapy, but significant AR signaling remains. Tissue-based analysis of steroids and AR signaling is critical to informing the search for optimal local and systemic control of high-risk prostate cancer.
Authors: Gerald L Andriole; David G Bostwick; Otis W Brawley; Leonard G Gomella; Michael Marberger; Francesco Montorsi; Curtis A Pettaway; Teuvo L Tammela; Claudio Teloken; Donald J Tindall; Matthew C Somerville; Timothy H Wilson; Ivy L Fowler; Roger S Rittmaster Journal: N Engl J Med Date: 2010-04-01 Impact factor: 91.245
Authors: Theo H van der Kwast; Mahul B Amin; Athanase Billis; Jonathan I Epstein; David Griffiths; Peter A Humphrey; Rodolfo Montironi; Thomas M Wheeler; John R Srigley; Lars Egevad; Brett Delahunt Journal: Mod Pathol Date: 2010-09-03 Impact factor: 7.842
Authors: Elahe A Mostaghel; Brett T Marck; Stephen R Plymate; Robert L Vessella; Stephen Balk; Alvin M Matsumoto; Peter S Nelson; R Bruce Montgomery Journal: Clin Cancer Res Date: 2011-08-01 Impact factor: 12.531
Authors: David J Mulholland; Linh M Tran; Yunfeng Li; Houjian Cai; Ashkan Morim; Shunyou Wang; Seema Plaisier; Isla P Garraway; Jiaoti Huang; Thomas G Graeber; Hong Wu Journal: Cancer Cell Date: 2011-05-27 Impact factor: 31.743
Authors: Rong Hu; Changxue Lu; Elahe A Mostaghel; Srinivasan Yegnasubramanian; Meltem Gurel; Clare Tannahill; Joanne Edwards; William B Isaacs; Peter S Nelson; Eric Bluemn; Stephen R Plymate; Jun Luo Journal: Cancer Res Date: 2012-06-18 Impact factor: 12.701
Authors: Elahe A Mostaghel; Linda Geng; Ilona Holcomb; Ilsa M Coleman; Jared Lucas; Lawrence D True; Peter S Nelson Journal: Cancer Res Date: 2010-02-02 Impact factor: 12.701
Authors: R Bruce Montgomery; Elahe A Mostaghel; Robert Vessella; David L Hess; Thomas F Kalhorn; Celestia S Higano; Lawrence D True; Peter S Nelson Journal: Cancer Res Date: 2008-06-01 Impact factor: 12.701
Authors: Zhiyong Guo; Xi Yang; Feng Sun; Richeng Jiang; Douglas E Linn; Hege Chen; Hegang Chen; Xiangtian Kong; Jonathan Melamed; Clifford G Tepper; Hsing-Jien Kung; Angela M H Brodie; Joanne Edwards; Yun Qiu Journal: Cancer Res Date: 2009-02-24 Impact factor: 12.701
Authors: Brett S Carver; Caren Chapinski; John Wongvipat; Haley Hieronymus; Yu Chen; Sarat Chandarlapaty; Vivek K Arora; Carl Le; Jason Koutcher; Howard Scher; Peter T Scardino; Neal Rosen; Charles L Sawyers Journal: Cancer Cell Date: 2011-05-17 Impact factor: 31.743
Authors: Andrea K Miyahira; Joshua M Lang; Robert B Den; Isla P Garraway; Tamara L Lotan; Ashley E Ross; Tanya Stoyanova; Steve Y Cho; Jonathan W Simons; Kenneth J Pienta; Howard R Soule Journal: Prostate Date: 2015-10-19 Impact factor: 4.104
Authors: Bruce Montgomery; Maria S Tretiakova; Anthony M Joshua; Martin E Gleave; Neil Fleshner; Glenn J Bubley; Elahe A Mostaghel; Kim N Chi; Daniel W Lin; Martin Sanda; William Novotny; Kenneth Wu; Philip W Kantoff; Brett T Marck; Stephen Plymate; Steven P Balk; Peter S Nelson; Alvin M Matsumoto; Rosina T Lis; Adam Kibel; Gabriel P Haas; Andrew Krivoshik; Alison Hannah; Mary-Ellen Taplin Journal: Clin Cancer Res Date: 2016-11-09 Impact factor: 12.531
Authors: Michelle E Melisko; Michael Assefa; Jimmy Hwang; Amy DeLuca; John W Park; Hope S Rugo Journal: Breast Cancer Res Treat Date: 2019-06-06 Impact factor: 4.872
Authors: Tianzhu Zang; Mary-Ellen Taplin; Daniel Tamae; Wanling Xie; Clementina Mesaros; Zhenwei Zhang; Glenn Bubley; Bruce Montgomery; Steven P Balk; Elahe A Mostaghel; Ian A Blair; Trevor M Penning Journal: Endocr Relat Cancer Date: 2017-06-29 Impact factor: 5.678
Authors: Mary-Ellen Taplin; Bruce Montgomery; Christopher J Logothetis; Glenn J Bubley; Jerome P Richie; Bruce L Dalkin; Martin G Sanda; John W Davis; Massimo Loda; Lawrence D True; Patricia Troncoso; Huihui Ye; Rosina T Lis; Brett T Marck; Alvin M Matsumoto; Steven P Balk; Elahe A Mostaghel; Trevor M Penning; Peter S Nelson; Wanling Xie; Zhenyang Jiang; Christopher M Haqq; Daniel Tamae; NamPhuong Tran; Weimin Peng; Thian Kheoh; Arturo Molina; Philip W Kantoff Journal: J Clin Oncol Date: 2014-10-13 Impact factor: 44.544
Authors: Jing Chao; Katya B Rubinow; Mario Kratz; John K Amory; Alvin M Matsumoto; Stephanie T Page Journal: J Clin Endocrinol Metab Date: 2016-08-02 Impact factor: 5.958